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Background/Aims: Endoscopic treatment has been broadly applied to superficial esophageal neoplasms. Endoscopic submucosal 
dissection (ESD) allows for high rates of en bloc resection, precise histological assessment, and low rates of local recurrence. The aim of 
this study was to evaluate the outcomes of ESD for superficial esophageal neoplasms.
Methods: We retrospectively reviewed 36 esophageal ESDs for superficial squamous neoplasms in 32 patients between March 2009 
and August 2014 at Gangnam Severance Hospital. 
Results: The median patient age was 64 years, and 30 men were included. The indications were early squamous cell carcinoma in 
26 lesions, adenoma with high-grade dysplasia in five lesions, and low-grade dysplasia in five lesions. The en bloc resection and R0 
resection rates were 97.2% (35 of 36) and 91.7% (33 of 36), respectively. Microperforation and post-ESD bleeding occurred in 5.6% (2 
of 36) and 5.6% (2 of 36), respectively. Post-ESD esophageal strictures developed in five patients (13.9%). Five patients (15.6%) had an 
additional treatment after ESD (concurrent chemoradiation therapy in three, radiation therapy in one, and surgery in one patient). 
There was no disease-specific mortality during the median follow-up of 31 months.
Conclusions: Favorable clinical outcomes were observed in ESD for superficial esophageal squamous neoplasms. Esophageal ESD 
could be a good treatment option in terms of efficacy and safety. Clin Endosc  2016;49:168-175
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INTRODUCTION
Endoscopic mucosal resection (EMR) has been generally 
applied to early gastrointestinal cancer.1 However, a critical 
drawback of EMR is that en bloc resection is difficult for tu-
mors >20 mm, and piecemeal resection should be performed 
instead.2 To overcome this and the other drawbacks not dis-
cussed here, endoscopic submucosal dissection (ESD) was 
developed.3 ESD allows for high rates of en bloc resection, 
precise histological assessment, and low rates of local recur-
rence.4,5 Thus, ESD is widely applied for the treatment of early 
gastric cancer and colorectal neoplasms, and the outcomes are 
reported to be good. However, endoscopists need to be aware 
that lymph node metastasis is likely to accompany esophageal 
squamous cell carcinoma even in the early stage.6-8
Endoscopic treatment has been broadly applied to super-
ficial esophageal neoplasms because of its convenience and 
minimal invasiveness.9 Considering that the morbidity and 
mortality of surgical treatment are relatively high, most pa-
tients are older in age, and the quality of life is poor after sur-
gery, endoscopic treatment for early esophageal cancer might 
have considerable benefits for patients who are not expected 
to have lymph node metastasis.10 According to recent data, 
endoscopic treatment is more effective and safer than surgical 
resection of superficial esophageal neoplasms.6,11
However, the level of difficulty in performing esophageal 
ESD is high because the narrow lumen obstructs the operative 
view, and because of movement due to heartbeat and respira-
tion. Additionally, there is a risk of perforation related to the 
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thin muscle wall and absence of a serosal layer. Furthermore, 
the lumen of the esophagus is narrow, and, therefore, post-
ESD esophageal strictures occur more frequently than stric-
tures in the stomach. When stricture occurs, multiple sessions 
of endoscopic balloon dilatation (EBD) are needed. Conse-
quently, it worsens the patients’ quality of life.12,13
As high-definition endoscopy with narrow-band imaging 
(NBI) was developed recently, the diagnosis of early esopha-
geal cancer or esophageal premalignant lesions has increased. 
Thus, how to treat these early neoplasms has become an im-
portant issue. The existing reports on the outcomes of esoph-
ageal ESD are mainly from Japan. The aim of this report was 
to integrate the data from Korea where ESD has been well 
established. We evaluated the efficacy and safety of ESD for 
superficial esophageal squamous neoplasms.
MATERIALS AND METHODS 
Patients
We retrospectively reviewed 36 esophageal ESDs for super-
ficial esophageal squamous neoplasms performed in 32 pa-
tients between March 2009 and August 2014 at Gangnam Sev-
erance Hospital. Superficial esophageal squamous neoplasm 
was defined as an adenoma with low-grade dysplasia, high-
grade dysplasia, and squamous cell carcinoma limited to the 
mucosal layer. Adenocarcinoma was excluded in this study to 
focus on squamous neoplasms that account for most of the 
esophageal neoplasms in the Far East regions. The Institution-
al Review Board of Gangnam Severance Hospital approved 
this study (IRB no. 2-2015-0339).
Evaluation of superficial esophageal neoplasm
The patients were evaluated by using magnifying endos-
copy with NBI. We also performed chromoendoscopy with 
Lugol’s solution. The superficial-type neoplasms were classi-
fied macroscopically into three types: 0-I, superficial and pro-
truding type (0-Ip, pedunculated; 0-Is, sessile); 0-II, superficial 
and flat type (0-IIa, slightly elevated; 0-IIb, completely flat; 
0-IIc, slightly depressed); and 0-III, superficial and distinctly 
depressed type. All diagnoses were confirmed with pre-ESD 
histological evaluation through biopsy. Concerning the his-
tological evaluation, in patients with superficial esophageal 
squamous neoplasms, we ascertained the tumor invasion 
depths and lymph node metastases by using endoscopic ul-
trasound (EUS) and computed tomography (CT). Also, we 
checked for distant metastasis through positron emission 
tomography (PET)-CT. ESD was not performed in patients 
suspected to have submucosal invasion, regional lymph node 
metastasis, or distant metastasis. 
Fig. 1. Endoscopic submucosal dissection of a superficial squamous cell carcinoma. (A, B) A slightly erythematous, flat lesion that is not stained with Lugol’s solu-
tion. (C, D) Submucosal dissection is made with a dual-knife after local submucosal injection. (E, F) The lesion is completely resected.
A  B  C
D  E  F
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ESD procedure
ESD was performed under moderate sedation with mid-
azolam and propofol. A video endoscope (GIF-H260Z, GIF-
Q260J; Olympus, Tokyo, Japan) equipped with a 4-mm trans-
parent cap (D-201-11804; Olympus) was used (Fig. 1).
The solution used for local submucosal injection was pre-
pared by mixing 10% glycerol solution and 0.005 mg/mL epi-
nephrine. In addition, hyaluronic acid (Endo-Mucoup; BMI 
Korea, Jeju, Korea) was used if necessary.
A dual-knife (KD-650Q; Olympus) or IT-knife 2 (KD-610L; 
Olympus) was used to perform the submucosal dissection 
with mainly the Swift coagulation mode of an electrosurgical 
generator (VIO 300D; Erbe Elektromedizin GmbH, Tübin-
gen, Germany). To control bleeding, hemostatic forceps (Co-
agrasper, FD-410LR; Olympus) with a soft coagulation mode 
(60-W output) were used, and carbon dioxide (CO2) was used 
for the insufflation.
Full-dose intravenous proton pump inhibitors and oral su-
cralfate were administered to the patient immediately after the 
procedure. If there was no evidence of complications such as 
bleeding or perforation, a liquid diet was offered on the next 
day, and the patient was discharged in a few days. Two skilled 
ESD endoscopists performed all procedures.
Complications
Microperforation was defined as radiographic evidence of 
free air or subcutaneous emphysema during the operation, 
without gross perforation defects in the esophageal wall. In 
the case of minor bleeding in the course of the operation, 
hemostasis was achieved immediately by means of thermo-
coagulation or hemoclipping. Massive bleeding during ESD 
was defined as bleeding that may necessitate the termination 
of the operation. Delayed postoperative bleeding was defined 
as a decreased blood hemoglobin level >2 g/dL observed 
5 days after the operation, accompanied by hematemesis 
or melena. In addition, post-ESD esophageal stricture was 
defined as dysphagia after the operation that required endo-
scopic treatment.
Histologic assessment 
The resected specimen, attached to a small plastic board 
and soaked in 4% formalin, was sent to a pathologist. Then, 
the specimen was fixed with 100% paraffin and cut into 2-mm 
thickness. Finally, hematoxylin and eosin staining was per-
formed. 
Histopathologic evaluation was performed to assess the 
tumor size, invasion depth, lymphovascular invasion, differ-
entiation grade, and resection margin. On the basis of the in-
vasion depth, intraepithelial cancer (m1), cancer invading the 
lamina propria (m2), cancer invading the muscularis mucosa 
(m3), and cancer invading the submucosa (sm) were diag-
nosed. 
En bloc resection was defined as removal of the lesion in 
one piece. Additionally, the resection margins were assessed 
according to the lateral and basal extensions of tumor cells 
as follows: R0, no cancerous cells seen microscopically; R1, 
cancerous cells can be seen microscopically; and Rx, not pos-
sible to establish. Also, curative resection was defined as en 
bloc resection with R0 resection for pathologically confirmed 
intramucosal tumor without lymphovascular invasion. The 
other resection was categorized as noncurative resection, and 
additional treatment was recommended. 
Follow-up
For patients who had curative resection through ESD, fol-
low-up upper gastrointestinal endoscopy with iodine staining 
was performed at 1, 3, and 6 months after the operation. 
Thereafter, it was performed every 6 months for 2 years, and 
on a yearly basis subsequently. For Lugol-voiding lesions, 
pathologic evaluation was performed through a biopsy. Chest 
and abdomen CT was performed 6 and 12 months after the 
operation. Moreover, PET-CT was performed at 12-month 
intervals.
Table 1. Clinicopathologic Features of the Patients and Tumors
Characteristic No. (%)
No. of patients (no. of lesions) 32 (36)
Age, yr, median (range) 64 (42–82)
Sex
   Male 30 (93.8)
   Female 2 (6.2)
Tumor location
   Upper third of the esophagus 3 (8.3)
   Middle third of the esophagus 13 (36.1)
   Lower third of the esophagus 17 (47.2)
   Esophagogastric junction 3 (8.3)
Tumor morphology
   Type 0-ls 1 (2.8)
   Type 0-lla 2 (5.6)
   Type 0-llb 32 (88.9)
   Type 0-llc 1 (2.8)
Tumor pathology
   Low-grade dysplasia 5 (13.9)
   High-grade dysplasia 5 (13.9)
   Squamous cell carcinoma 26 (72.2)
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RESULTS
Clinicopathological characteristics
In total, 32 patients (median age, 64 years; range, 42 to 82 
years; 30 men) were enrolled and 36 lesions were treated with 
ESD. Seventeen lesions (47.2%) were located in the lower 
esophagus. Most of the tumors (88.9%) were macroscopic type 
0-IIb. There were 26 squamous cell carcinoma lesions (72.2%) 
(Table 1). Among these patients, two had a history of concur-
rent chemoradiation therapy (CCRTx) for esophageal cancer 
and had ESD for recurrent esophageal cancer.
Treatment outcomes
The median size of the resected specimen was 28 mm (range, 
12 to 64), and the median tumor size was 17 mm (range, 3 to 
52). Six specimens extended to more than three-fourth of the 
circumference of the esophageal lumen. In the case of inva-
sion depth, there were seven m3 lesions and five sm lesions.
En bloc resection was achieved in 35 lesions (97.2%) and R0 
resection in 33 lesions (91.7%). For one lesion, en bloc resection 
could not be performed because the patient had advanced 
liver cirrhosis and bleeding that obstructed the operative view. 
Furthermore, microperforation was suspected. Finally, the 
procedure was ceased because of the risk of mediastinitis.
The total number of patients in whom R0 resection was not 
performed was three, including the above-mentioned patient. 
One patient had a positive basal margin (R1 resection), and 
the other patient had extension of carcinoma in situ along the 
submucosal gland (Rx resection) (Table 2).
Complications
In the immediate complications, microperforation was 
observed in two lesions (5.6%). Those two patients fully re-
covered with supportive medical treatment. None of the cases 
needed termination of ESD because of massive bleeding.
In the latent complications, delayed bleeding was observed 
in two lesions (5.6%), which was successfully treated with 
endoscopic hemostasis. Symptomatic post-ESD esophageal 
strictures occurred in five lesions (13.9%). The resected speci-
mens of those patients extended to more than three-fourth of 
the circumference of the esophageal lumen. They were treated 
with EBD with or without local steroid injections. On average, 
EBD was performed three times (range, two to nine times), 
and a self-expandable metal stent was inserted as a temporary 
measure in two patients.
A gross perforation event during EBD occurred in one 
patient who had a post-ESD stricture. The patient was man-
aged with temporary stenting and percutaneous endoscopic 
gastrostomy feeding. There was no procedure-related death 
(Table 3).
Additional treatment
Curative resection was performed in 25 patients (29 lesions, 
80.6%). Noncurative resection was performed in six patients; 
in five of these patients, the lesion invaded the sm layer, and 
one patient had an m3 tumor with lymphovascular invasion.
One patient whose lesion invaded the sm layer did not un-
dergo additional treatment because this patient has a history 
of radiotherapy for breast cancer and refused additional treat-
Table 2. Treatment Outcomes
Characteristic Value
Specimen size, mm 28 (12–64)
Tumor size, mm 17 (3–52)
Circumference of the resected specimen 
   <1/2 21 (60)
   <3/4 8 (22.9)
   >3/4 6 (17.1)
ESD procedure time, min 36.5 (10–240)
Tumor depth
   Low-grade dysplasia 5 (13.9)
   High-grade dysplasia 5 (13.9)
   Epithelial layer (m1) 6 (16.7)
   Lamina propria (m2) 8 (22.2)
   Muscularis mucosa (m3) 7 (19.4)
   Submucosal layer (sm) 5 (13.9)
En bloc resection 35/36 (97.2)
R0 resection 33/36 (91.7)
Length of hospitalization, day 4 (3–13)
Values are presented as mean (range) or number (%).
ESD, endoscopic submucosal dissection.




Massive bleeding during ESD 0/36 (0)
Latent complications
Delayed bleeding 2/36 (5.6)
Post-ESD esophageal stricture 5/36 (13.9)
EBD or EBD+local steroid injections 5
No. of EBD sessions 3 (2–9)
Temporary SEMS 2
Values are presented as number (%) or mean (range).
ESD, endoscopic submucosal dissection; EBD, endoscopic balloon 
dilatation; SEMS, self-expandable metal stent.
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ment. The other five patients (15.6%) had additional treatment 
for esophageal cancer after ESD (CCRTx in three patients, 
radiation therapy in one patient, and surgery in one patient). 
The patient who underwent esophagectomy was found to 
have lymph node recurrence at 24 months after the operation, 
and additional CCRTx was performed. Thereafter, the patient 
was followed without recurrence. 
There was no recurrence or disease-specific mortality 
during a median follow-up of 31 months (Fig. 2).
DISCUSSION
ESD has been broadly applied to superficial esophageal 
neoplasms, and related studies have been performed mostly in 
Japan. Recently, there was a report of a small series in Korea.14 
This study also showed that ESD is effective and safe for the 
treatment of superficial esophageal neoplasms.
The results showed an en bloc resection rate of 97.2% and an 
R0 resection rate of 91.7%, which were comparable to those 
of precedent studies, and the rate of major complications 
such as perforation or stricture was also comparable to that of 
earlier studies.3,15-17 In addition, there was no local or distant 
recurrence in the median follow-up of 27 months when the 
patients achieved curative resection.
The most critical point in endoscopic treatment for gastro-
intestinal cancer is that the cancer should be completely cured 
with endoscopic resection. To satisfy this expectation, R0 re-
section needs to be performed, and at the same time, regional 
lymph node metastasis or distant metastasis should not exist. 
Unlike stomach cancer or colorectal cancer, esophageal cancer 
is accompanied by lymph node metastasis in the early stage, 
and this should be understood well before planning the treat-
ment strategy.
According to previous studies, regional lymph node metas-
tasis occurred in 8% to 18% of patients with m3 invasion and 
36 Attempted esophageal ESD
No recurrence (median follow-up for 31 months)
5 Additional treatment
35 En bloc resection






  5 sm invasion
  1 m3 invasion with lymphovascular invasion
29 Curative resection (with m3 layer & no 
lymphovascular invasion)
1 No additional 
treatment due to 





1 RTx 3 CCRTx
Fig. 2. Additional treatment and follow-up of 36 superficial squamous neoplasms in 32 patients who underwent endoscopic submucosal dissection (ESD). RTx, ra-
diotherapy; LN, lymph node; CCRTx, concurrent chemoradiation therapy. 
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17% to 53% of patients with sm1 invasion.6-8 On the basis of 
those results, ESD for early esophageal squamous cell carcino-
ma limited to the m1/m2 layer has been generally accepted. 
However, the criteria have not been established to date.
In their study of m3 or sm1 superficial esophageal car-
cinoma patients, Higuchi et al.18 reported that tumors with 
lymphatic invasion, a tumor size of at least 25 mm, and a 
lamina muscularis mucosa invasion width of at least 2,500 
µm are at a high risk for lymph node metastasis. Additionally, 
they pointed out that patients who do not have those tumor 
characteristics can be considered for endoscopic treatment 
even when they have m3 or sm1 invasion.18 Kim et al.19 ana-
lyzed 200 patients with T1 esophageal carcinoma who were 
treated surgically, and concluded that a tumor size >20 mm, 
endoscopically nonflat type, and lymphatic invasion were sig-
nificant independent risk factors for lymph node metastasis. 
They suggested that considering these factors, endoscopic 
treatment can be performed.19 In study of Eguchi et al.8 of 
464 patients with superficial squamous cell carcinoma of the 
esophagus who had undergone a radical esophagectomy with 
lymph node dissection, four of 38 patients (10.3%) with m3 
lesions without lymphatic invasion had lymph node metas-
tasis, whereas five of 12 patients (41.7%) with m3 lesions and 
lymphatic invasion had lymph node metastasis. The authors 
suggested that m3 lesions without lymphatic invasion can be 
followed after endoscopic treatment without any additional 
treatment.8
We considered the curative resection complete if there 
was no lymphovascular invasion in the resected specimen of 
the patients who had m3 invasion, and regional lymph node 
metastasis was not observed on EUS, CT, and PET-CT. In this 
study, seven patients had m3 invasion, and among the pa-
tients, one patient had lymphovascular invasion. The patient 
who had m3 layer and lymphovascular invasion underwent 
CCRTx as an additional treatment. The other six patients 
without lymphovascular invasion did not undergo additional 
treatment but were closely followed. Local or distant recur-
rence was not observed with the six patients in 44 months. 
However, there is no current standard guideline for m3 squa-
mous cell carcinoma without lymphovascular invasion after 
en bloc resection with ESD.
Patients with sm invasion, regardless of the presence of 
lymphovascular invasion, are inappropriate candidates for 
ESD. According to previous studies, one factor that can pre-
dict sm invasion is gross tumor shape. Endo analyzed the 
invasion depth according to gross shape in superficial esoph-
ageal cancer. Flat-type (llb) tumors showed sm invasion in 
0% (0 of 12), whereas type l, lla, llc, lll, and combined lesions 
showed sm invasion in 100% (53 of 53), 66.7% (4 of 6), 38.4% 
(30 of 78), 100% (21 of 21), and 97.7% (42 of 43), respectively.20 
In our study, the total number of patients with nonflat-type 
lesions was four. One (lla lesion) had a sm lesion, whereas 
another (ls lesion) had an m3 lesion with lymphatic invasion. 
CCRTx was performed as an additional treatment. From the 
case of a nonflat-type lesion, the possibility of noncurative 
resection is high; thus, other treatment modalities should 
be considered. In addition, the author of this study does not 
consider ESD as a primary treatment for nonflat-type lesions. 
The establishment of standard indications for ESD through 
further studies is necessary in the future.
In this study, one patient showed extension of carcinoma in 
situ along the submucosal gland. According to the Japanese 
guidelines for clinical and pathological studies on carcino-
ma of the esophagus, tumors with ductal involvement that 
extends to the submucosal gland but does not invade the 
submucosal stroma should not be classified as submucosal 
carcinoma.21 Also, Tajima et al.22 analyzed 201 surgically re-
sected superficial squamous cell carcinomas and concluded 
that ductal involvement as a pathway of tumor spread to the 
deeper layer is of little significance in squamous cell carci-
noma of the esophagus, and that mucosal carcinomas with 
ductal involvement that extends to the submucosa should not 
be classified as submucosal carcinoma. On the basis of these 
results, the lesion was not classified as submucosal carcinoma. 
However, we considered the procedure for this lesion as Rx 
resection because the submucosal glands of the lesion were 
not fully removed. In esophageal ESD, there might be ductal 
extension of tumor cells in the submucosal gland in carcino-
ma in situ. Thus, it is technically important that submucosal 
connective tissues beneath the proper esophageal glands are 
fully resected to evaluate the ductal extension of tumor cells. 
The esophageal ESD specimen from which the submucosal 
glands were not completely resected cannot be classified as an 
R0 resection. The patient indicated for an Rx resection in the 
current study did not undergo additional treatment, and local 
or distant recurrence was not observed during 66 months of 
follow-up.
In this study, five of the six patients who had noncurative 
resection underwent additional treatment, and one patient 
from that group underwent esophagectomy but showed 
lymph node recurrence. Then, the patient underwent CCRTx. 
In light of this case, surgery as an additional treatment is not 
the best option. Considering the surgical risk, chemotherapy 
or CCRTx needs to be applied depending on the patient. To 
date, no study has determined which modality is appropriate 
for patients who undergo noncurative resection as an addi-
tional treatment. Further study on this issue is necessary.
If the muscular layer is injured during SD, perforation 
could occur because the esophagus does not have a serosal 
layer. In such cases, perforation could result in mediastinitis, 
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and therefore, esophageal ESD is considered a risky proce-
dure. In this study, gross perforation did not occur; however, 
microperforation and accompanying subcutaneous emphy-
sema and mediastinitis occurred in two patients (5.6%). In 
previous studies, the rate of perforation during ESD was 2.6% 
to 6.9%, which is comparable to that of this study.3,16,17 Imme-
diate closure through endoscopic clipping was performed in 
the suspected region, and those two patients recovered with 
supportive care such as fasting and intravenous antibiotics. 
Delayed bleeding was observed in the two patients (5.6%), 
which was treated with endoscopic thermocoagulation and 
hemoclipping. The role of second-look endoscopy has not 
been determined in esophageal ESD, and second-look endos-
copy was not performed in this study. Further study to set 
the role of second-look endoscopy is necessary. There was no 
procedure-related mortality in this study.
Esophageal ESD has lower morbidity and mortality rates 
than surgery; however, the candidates need to be chosen 
with consideration of the above complications. As previously 
stated, the advanced liver cirrhosis patient whose ESD had 
been stopped had a high tendency for bleeding as a result of 
thrombocytopenia and prolonged prothrombin time. Severe 
bleeding obstructed the operative view, and microperforation 
occurred as a result. Moreover, if mediastinitis had occurred, 
recovery from infection might have been difficult. Therefore, 
the procedure had to be stopped. After the procedure, preven-
tive antibiotics were started. Mediastinitis did not occur but 
delayed bleeding occurred 10 days after the procedure. This 
candidate was inappropriate for esophageal ESD, and this case 
indicates the importance of careful candidate selection.
During the long-term follow-up, post-ESD stricture after 
esophageal ESD is a critical complication that affects patients’ 
quality of life. According to recent studies, post-ESD stricture 
occurred in 5% to 17.2% of patients.3,23,24 Ono’s study of 65 
patients with superficial esophageal squamous cell neoplasms 
revealed that a circumferential extension of >3/4 and a his-
tologic depth of up to the m2 layer are reliable risk factors 
for post-ESD stricture.12 In addition, study of Mizuta et al.25 
proved that circumferential mucosal defect size is a predictive 
factor in post-ESD esophageal stricture, and circumferential 
extension >71% of the esophageal lumen has the highest sen-
sitivity (100%) and specificity (97.1%) in predicting post-ESD 
stricture. In this study, of the six patients in whom the lesion 
extended to more than three-fourth of the luminal circumfer-
ence, one patient had sm invasion and underwent esophagec-
tomy as an additive treatment. The other five patients experi-
enced post-ESD strictures. Overall, circumferential extension 
is the most reliable predictive factor for post-ESD stricture, 
and prevention of stricture is the most critical issue among 
those patients.
The conventional method that has been adopted to prevent 
post-ESD stricture is EBD. EBD is simple and conventional; 
however, it generally should be performed in multiple ses-
sions, and there is a perforation risk.26,27 Recently, preemptive 
intralesional steroid injections and systemic steroid adminis-
tration have been adopted. In study of Hashimoto et al.,28 41 
consecutive patients who had semi-circumferential mucosal 
defects after ESD, the group who underwent endoscopic 
triamcinolone injections had a significantly lower incidence 
of stricture, the number of required EBDs was also lower, 
and no adverse effects or complications were associated with 
the triamcinolone injections. Isomoto et al.26 analyzed seven 
patients who underwent wholly circumferential ESD for 
superficial esophageal squamous cell carcinoma and com-
pared the prophylactic EBD group and the oral prednisolone 
administration group. The treatment in the latter group was 
more effective in controlling post-ESD strictures and in pre-
venting repeated EBD, and was not accompanied by adverse 
events.26 Recently, new technology with biodegradable stents 
or autologous oral mucosal sheets has been reported.29,30 It is 
important to apply proper prevention methods, considering 
the lesion and the characteristics of the patients. Preemptive 
EBD was the conventional modality at the time when post-
ESD strictures occurred in the patients of this study. There-
fore, preemptive local steroid injections or systemic steroid 
administration could not be performed. Preemptive EBD 
was applied to all patients. Currently, they are being followed 
without a recurrence of symptoms.
In conclusion, this study shows favorable clinical outcomes 
in ESD for superficial esophageal squamous neoplasms, and 
reveals that esophageal ESD is a relatively safe, technically 
feasible, and effective treatment. Additional treatment needs 
to be considered after assessing the tumor invasion depth, 
presence of R0 resection, and presence of lymphovascular in-
vasion. Additionally, in patients who undergo widespread cir-
cumferential resection, paying attention to prevent strictures 
is important. Although further massive studies with long-
term follow-up are needed, ESD should be considered as the 
useful treatment option for superficial esophageal squamous 
neoplasms.
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